everolimus

ROUTE	ONSET	PEAK	DURATION
PO	unknown	1–2 hr	24 hr

Advanced Renal Cell Carcinoma, Advanced Progressive Neuroendocrine Tumors, Advanced Neuroendocrine Tumors, Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer, and Renal Angiomyolipoma With Tuberous Sclerosis Complex (Afinitor)

PO (Adults ): 10 mg once daily until disease progression or unacceptable toxicity; Concurrent use of P-gp inhibitor and moderate CYP3A4 inhibitor: 2.5 mg once daily until disease progression or unacceptable toxicity; Concurrent use of P-gp inducer and strong CYP3A4 inducer:↑ dose in 5 mg increments up to 20 mg once daily; continue until disease progression or unacceptable toxicity.

Hepatic Impairment

PO (Adults ): Mild hepatic impairment: 7.5 mg once daily until disease progression or unacceptable toxicity; may ↓ to 5 mg once daily if not well tolerated; Moderate hepatic impairment: 5 mg once daily until disease progression or unacceptable toxicity; may ↓ to 2.5 mg once daily if not well tolerated; Severe hepatic impairment: 2.5 mg once daily until disease progression or unacceptable toxicity.

Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex (Afinitor)

PO (Adults and Children ≥1 yr): 4.5 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity; Concurrent use of P-gp inhibitor and moderate CYP3A4 inhibitor: 2.25 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity; Concurrent use of P-gp inducer and strong CYP3A4 inducer: 9 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity.

Hepatic Impairment

PO (Adults and Children ≥1 yr): Severe hepatic impairment: 2.5 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity.

Tuberous Sclerosis Complex-Associated Partial-Onset Seizures (Afinitor)

PO (Adults and Children ≥2 yr): 5 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity; Concurrent use of P-gp inhibitor and moderate CYP3A4 inhibitor: 2.5 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity; Concurrent use of P-gp inducer and strong CYP3A4 inducer: 10 mg/m² once daily. Titrate as needed, at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity.

Hepatic Impairment

PO (Adults and Children ≥2 yr): Severe hepatic impairment: 2.5 mg/m² once daily. Titrate as needed at 2-wk intervals to achieve recommended whole blood trough concentration. Continue until disease progression or unacceptable toxicity.

Kidney Transplantation (Zortress)

PO (Adults ): 0.75 mg twice daily (with reduced-dose cyclosporine); titrate to achieve recommended whole blood trough concentration.

Hepatic Impairment

PO (Adults ): Mild hepatic impairment :↓ daily dose by 33%; Moderate or severe hepatic impairment:↓ daily dose by 50%.

Liver Transplantation (Zortress)

PO (Adults ): 1 mg twice daily (with reduced-dose tacrolimus) (start ≥30 days post-transplant); titrate to achieve recommended whole blood trough concentration.

Hepatic Impairment

PO (Adults ): Mild hepatic impairment :↓ daily dose by 33%; Moderate or severe hepatic impairment:↓ daily dose by 50%.

Availability ⬆ ⬇

(Generic available)

Tablets (Afinitor): 2.5 mg; 5 mg; 7.5 mg; 10 mg
Tablets for oral suspension (Afinitor Disperz): 2 mg; 3 mg; 5 mg
Tablets (Zortress): 0.25 mg; 0.5 mg; 0.75 mg; 1 mg

Assessment ⬆ ⬇

Assess for symptoms of noninfectious pneumonitis (hypoxia, pleural effusion, cough, dyspnea) during therapy. If symptoms are mild, therapy may continue. If Grade 2 pneumonitis occurs, hold therapy until Grade ≤1; reinitiate everolimus at 50% of previous dose. Permanently discontinue if does not resolve or improve to Grade 1 within 4 wk. If Grade 3 pneumonitis occurs, hold therapy until Grade ≤1; resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. Permanently discontinue everolimus if Grade 3 pneumonitis recurs. If Grade 4 pneumonitis occurs, permanently discontinue everolimus.
Assess for mouth ulcers, stomatitis, or oral mucositis; usually occurs within first 8 wk of therapy. Begin dexamethasone alcohol-free oral solution as a swish-and-spit mouthwash when starting therapy to reduce incidence and severity of stomatitis. Topical treatments may be used; avoid peroxide-containing mouthwashes and antifungals unless fungal infection has been diagnosed. If Grade 2 stomatitis occurs, hold therapy until Grade ≤1; resume at previous dose. If Grade 2 recurs, withhold until Grade ≤1; resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. If Grade 3 stomatitis occurs, hold therapy until Grade ≤1; hold until Grade 0–1; resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. If Grade 4 stomatitis occurs, permanently discontinue everolimus.
Assess for signs and symptoms of systemic fungal infections (fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, serious systemic illness with or without concurrent shock). Withhold therapy until infection has been diagnosed and adequately treated.
Monitor for signs and symptoms of hypersensitivity reactions (anaphylaxis, dyspnea, flushing, chest pain, angioedema) during therapy. If severe hypersensitivity reaction occurs, permanently discontinue everolimus.

Lab Test Considerations:

Verify negative pregnancy test before starting therapy.
- Monitor renal function before and periodically during therapy. May ↑ BUN, serum creatinine, and proteinuria.
- Monitor fasting serum glucose and lipid profile prior to and periodically during therapy. May ↑ cholesterol, triglycerides, and glucose. Attempt to achieve optimal glucose and lipid control prior to therapy. If Grade 3 metabolic events (hyperglycemia, dyslipidemia) occur, hold until improvement to Grade ≤2. Resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength.
- Monitor CBC before and every 6 mo for 1st yr of therapy and annually thereafter; may ↓ hemoglobin, lymphocytes, neutrophils, and platelets. If Grade 2 thrombocytopenia occurs, hold dose until Grade ≤1; resume at same dose. If Grade 3 or 4 thrombocytopenia occurs, hold until improvement to Grade ≤2. Resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. If Grade 3 neutropenia occurs, hold dose until Grade ≤1; resume at same dose. If Grade 4 neutropenia occurs, hold until improvement to Grade ≤2. Resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. If Grade 3 febrile neutropenia occurs, hold until improvement to Grade ≤2 and no fever. Resume at 50% of previous dose. Change to every other day if dose is lower than lowest available strength. If Grade 4 febrile neutropenia occurs, permanently discontinue everolimus.
- May ↑ AST, ALT, phosphate, and bilirubin.
- Afinitor: Monitor Afinitor trough levels 2 wk after initiation of therapy, a change in dose, a change in coadministration of CYP3A4 and/or P-gp inducers or inhibitors, change in hepatic function, or change in dose form between everolimus tablets and Disperz. Once at a stable dose, monitor trough concentrations every 3–6 mo in patients with changing body surface area or every 6–12 mo in patients with stable body surface area for duration of treatment. Therapeutic blood concentrations are 5–15 ng/mL (Afinitor). If trough concentration <5 ng/mL, ↑ daily dose by 2.5 mg in patients taking tablets and 2 mg for Disperz. If trough concentration >15 ng/mL, ↓ daily dose by 2.5 mg in patients taking tablets and 2 mg for Disperz. If dose ↓ is required with lowest dose, administer every other day. Do not combine dose forms to achieve dose.
- ZortressTherapeutic blood concentrations are 3–8 ng/mL via the LCMSMS assay. Base dose adjustments of Zortress on trough concentrations obtained 4 or 5 days after a previous dosing change. Adjust dose if trough concentration <3 ng/mL by doubling dose using available tablet strengths (0.25 mg, 0.5 mg, or 0.75 mg). If trough concentration >8 ng/mL on two consecutive measures, ↓ dose of Zortress by 0.25 mg twice daily.
- Zortress (Kidney Transplantation)Both cyclosporine doses and the target range for whole blood trough concentrations should be ↓ when given in a regimen with Zortress in order to minimize the risk of nephrotoxicity. The recommended cyclosporine therapeutic ranges when administered with Zortress are 100–200 ng/mL through Month 1 post-transplant, 75–150 ng/mL at Months 2 and 3 post-transplant, 50–100 ng/mL at Month 4 post-transplant, and 25–50 ng/mL from Month 6 through Month 12 post-transplant. Cyclosporine, USP Modified is to be administered as oral capsules twice daily unless cyclosporine oral solution or IV administration of cyclosporine cannot be avoided. Cyclosporine, USP Modified should be initiated as soon as possible and no later than 48 hr after reperfusion of the graft and dose adjusted to target concentrations from Day 5 onward. If impairment of renal function is progressive, the treatment regimen should be adjusted. In renal transplant patients, the cyclosporine dose should be based on cyclosporine whole blood trough concentrations. Prior to dose ↓ of cyclosporine, steady-state everolimus whole blood trough concentration should be ≥3 ng/mL. Everolimus concentrations may ↓ if cyclosporine exposure is ↓.
- Zortress (Liver Transplantation)Both tacrolimus doses and the target range for whole blood trough concentrations should be ↓ when administered with Zortress in order to minimize the potential risk of nephrotoxicity. The recommended tacrolimus therapeutic range when administered with Zortress are whole blood trough concentrations of 3–5 ng/mL by 3 wk after the first dose of Zortress (approximately Month 2) and through Month 12 post-transplant. Tacrolimus is to be administered as oral capsules twice daily unless IV administration of tacrolimus cannot be avoided. In liver transplant patients, the tacrolimus dose should be based on tacrolimus whole blood trough concentrations. Prior to dose ↓ of tacrolimus, steady-state everolimus whole blood trough concentration should be ≥3 ng/mL. Tacrolimus does not affect everolimus trough concentrations; everolimus concentrations do not ↓ if the tacrolimus exposure is ↓.

Implementation ⬆ ⬇

May impair wound healing. Hold everolimus for ≥1 wk before and ≥2 wk after elective surgery to ensure adequate wound healing.
Zortress: Antimicrobial prophylaxis for Pneumocystis jirovecipneumonia and prophylaxis for cytomegalovirus is recommended in transplant recipients.
PO: Administer at the same time each day consistently with or without food, followed by a whole glass of water. DNC: Swallow tablets whole; do not break, crush, or chew.
- Do not combine the two dose forms (Afinitor Tablets and Afinitor Disperz) to achieve the desired total dose. Use one dose form or the other.
- Administer Disperz, dispersible tablet, as a suspension only. Wear gloves to avoid possible contact with everolimus when preparing suspensions for another person. Place dose in 10 mL syringe; do not exceed 10 mg/syringe. If higher dose required, use additional syringe. Do not break or crush tablets. Draw 5 mL water and 4 mL of air into syringe. Place filled syringe into container (tip up) for 3 min until tablets are in suspension. Invert syringe five times immediately prior to administration. Administer immediately after preparation; discard suspension if not administered within 60 min after preparation. After administration, draw 5 mL of water and 4 mL of air into same syringe, and swirl contents to suspend remaining particles. Administer entire contents of syringe. Can also be dispersed using same technique and 25 mL water in small glass.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take everolimus at the same time each day as directed. Take missed doses as soon as remembered up to 6 hr after time of normal dose. If >6 hr after normal dose, omit dose for that day and take next dose next day; do not take two doses to make up missed dose. Do not eat grapefruit or drink grapefruit juice during therapy. Advise patient to read Patient Information prior to beginning therapy and with each Rx refill in case of new information.
Advise patient to report worsening respiratory symptoms or signs of infection (new or worsening cough, shortness of breath, chest pain, difficulty breathing or wheezing, fever, chills, skin rash, joint pain and inflammation, tiredness, loss of appetite, nausea, pale stool or dark urine, yellowing of the skin, pain in upper right side) or severe allergic reaction (rash; itching; hives; flushing; trouble breathing or swallowing; chest pain; dizziness; trouble breathing; swelling of tongue, mouth, or throat) to health care provider promptly.
Inform patient that mouth sores may occur. Consult health care provider for treatment if pain, discomfort, or open sores in mouth occur. May require special mouthwash or gel.
Instruct patient to avoid use of live vaccines and close contact with those who have received live vaccines.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications, especially St. John's wort.
Notify health care provider of everolimus therapy before treatment or surgery. May require temporarily stopping everolimus.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception during and for up to 8 wk after last dose, male patients with female partners of reproductive potential to use effective contraception during and for up to 4 wk after last dose, and to notify health care provider if pregnancy is planned or suspected. Advise female patients to avoid breastfeeding during and for 2 wk after last dose. May impair fertility in female and male patients.
Emphasize the importance of routine blood tests to determine effectiveness and side effects.

Evaluation/Desired Outcomes ⬆ ⬇

Decreased spread of tumor. Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.
Prevention of kidney or liver transplant rejection.
Reduced seizure frequency.

US Brand Names ⬆ ⬇

Afinitor, Afinitor Disperz, Zortress

Code ⬆

NDC Code

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0470- Everolimus
  - 0054-0470-21- 60 TABLET in 1 BOTTLE (0054-0470-21)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0471- Everolimus
  - 0054-0471-21- 60 TABLET in 1 BOTTLE (0054-0471-21)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0472- Everolimus
  - 0054-0472-21- 60 TABLET in 1 BOTTLE (0054-0472-21)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0480- Everolimus
  - 0054-0480-13- 30 TABLET in 1 BOTTLE (0054-0480-13)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0481- Everolimus
  - 0054-0481-13- 30 TABLET in 1 BOTTLE (0054-0481-13)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0482- Everolimus
  - 0054-0482-13- 30 TABLET in 1 BOTTLE (0054-0482-13)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0497- Everolimus
  - 0054-0497-13- 30 TABLET in 1 BOTTLE (0054-0497-13)

0054- Hikma Pharmaceuticals USA Inc.
- 0054-0604- Everolimus
  - 0054-0604-21- 60 TABLET in 1 BOTTLE (0054-0604-21)

0078- Novartis Pharmaceuticals Corporation
- 0078-0414- Zortress
  - 0078-0414-20- 60 BLISTER PACK in 1 BOX (0078-0414-20) / 1 TABLET in 1 BLISTER PACK (0078-0414-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0415- Zortress
  - 0078-0415-20- 60 BLISTER PACK in 1 BOX (0078-0415-20) / 1 TABLET in 1 BLISTER PACK (0078-0415-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0417- Zortress
  - 0078-0417-20- 60 BLISTER PACK in 1 BOX (0078-0417-20) / 1 TABLET in 1 BLISTER PACK (0078-0417-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0422- Zortress
  - 0078-0422-20- 60 BLISTER PACK in 1 BOX (0078-0422-20) / 1 TABLET in 1 BLISTER PACK (0078-0422-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0566- Afinitor
  - 0078-0566-51- 28 BLISTER PACK in 1 CARTON (0078-0566-51) / 1 TABLET in 1 BLISTER PACK (0078-0566-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0567- Afinitor
  - 0078-0567-51- 28 BLISTER PACK in 1 CARTON (0078-0567-51) / 1 TABLET in 1 BLISTER PACK (0078-0567-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0594- Afinitor
  - 0078-0594-51- 28 BLISTER PACK in 1 CARTON (0078-0594-51) / 1 TABLET in 1 BLISTER PACK (0078-0594-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0620- Afinitor
  - 0078-0620-51- 28 BLISTER PACK in 1 CARTON (0078-0620-51) / 1 TABLET in 1 BLISTER PACK (0078-0620-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0626- Afinitor Disperz
  - 0078-0626-51- 28 BLISTER PACK in 1 CARTON (0078-0626-51) / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (0078-0626-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0627- Afinitor Disperz
  - 0078-0627-51- 28 BLISTER PACK in 1 CARTON (0078-0627-51) / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (0078-0627-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-0628- Afinitor Disperz
  - 0078-0628-51- 28 BLISTER PACK in 1 CARTON (0078-0628-51) / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (0078-0628-61)

0078- Novartis Pharmaceuticals Corporation
- 0078-1406-
  - 0078-1406-07- 5 kg in 1 BAG (0078-1406-07)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7766- Everolimus
  - 0093-7766-24- 28 BLISTER PACK in 1 CARTON (0093-7766-24) / 1 TABLET in 1 BLISTER PACK (0093-7766-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7767- Everolimus
  - 0093-7767-24- 28 BLISTER PACK in 1 CARTON (0093-7767-24) / 1 TABLET in 1 BLISTER PACK (0093-7767-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7768- Everolimus
  - 0093-7768-24- 28 BLISTER PACK in 1 CARTON (0093-7768-24) / 1 TABLET in 1 BLISTER PACK (0093-7768-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7769- Everolimus
  - 0093-7769-24- 28 BLISTER PACK in 1 CARTON (0093-7769-24) / 1 TABLET in 1 BLISTER PACK (0093-7769-19)

0245- Upsher-Smith Laboratories, LLC
- 0245-0822- TORPENZ
  - 0245-0822-30- 30 TABLET in 1 BOTTLE (0245-0822-30)

0245- Upsher-Smith Laboratories, LLC
- 0245-0823- TORPENZ
  - 0245-0823-30- 30 TABLET in 1 BOTTLE (0245-0823-30)

0245- Upsher-Smith Laboratories, LLC
- 0245-0824- TORPENZ
  - 0245-0824-30- 30 TABLET in 1 BOTTLE (0245-0824-30)

0245- Upsher-Smith Laboratories, LLC
- 0245-0825- TORPENZ
  - 0245-0825-30- 30 TABLET in 1 BOTTLE (0245-0825-30)

0378- Mylan Pharmaceuticals Inc.
- 0378-0005- Everolimus
  - 0378-0005-85- 4 BLISTER PACK in 1 CARTON (0378-0005-85) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK

0378- Mylan Pharmaceuticals Inc.
- 0378-0006- Everolimus
  - 0378-0006-85- 4 BLISTER PACK in 1 CARTON (0378-0006-85) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK

0378- Mylan Pharmaceuticals Inc.
- 0378-0007- Everolimus
  - 0378-0007-85- 4 BLISTER PACK in 1 CARTON (0378-0007-85) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK

17088- Novartis Pharma Stein AG
- 17088-0107-
  - 17088-0107-1- 25000 TABLET, FOR SUSPENSION in 1 DRUM (17088-0107-1)

17088- Novartis Pharma Stein AG
- 17088-0114-
  - 17088-0114-1- 25000 TABLET, FOR SUSPENSION in 1 DRUM (17088-0114-1)

17088- Novartis Pharma Stein AG
- 17088-0135-
  17088-0135-1- 25000 TABLET in 1 DRUM (17088-0135-1)

17088- Novartis Pharma Stein AG
- 17088-0142-
  17088-0142-1- 25000 TABLET in 1 DRUM (17088-0142-1)

17088- Novartis Pharma Stein AG
- 17088-0149-
  17088-0149-1- 25000 TABLET in 1 DRUM (17088-0149-1)

17088- Novartis Pharma Stein AG
- 17088-0247-
  17088-0247-1- 25000 TABLET, FOR SUSPENSION in 1 DRUM (17088-0247-1)

17088- Novartis Pharma Stein AG
- 17088-0261-
  17088-0261-1- 25000 TABLET in 1 DRUM (17088-0261-1)

17404- Farmhispania, S.A.
- 17404-1027-
  17404-1027-1- 1 BAG in 1 DRUM (17404-1027-1) / 1 kg in 1 BAG

49884- ENDO USA, Inc.
- 49884-119- Everolimus
  49884-119-91- 28 BLISTER PACK in 1 CARTON (49884-119-91) / 1 TABLET in 1 BLISTER PACK (49884-119-52)

49884- ENDO USA, Inc.
- 49884-125- Everolimus
  - 49884-125-91- 28 BLISTER PACK in 1 CARTON (49884-125-91) / 1 TABLET in 1 BLISTER PACK (49884-125-52)

49884- ENDO USA, Inc.
- 49884-127- Everolimus
  - 49884-127-91- 28 BLISTER PACK in 1 CARTON (49884-127-91) / 1 TABLET in 1 BLISTER PACK (49884-127-52)

49884- ENDO USA, Inc.
- 49884-128- Everolimus
  - 49884-128-91- 4 BLISTER PACK in 1 CARTON (49884-128-91) / 7 TABLET in 1 BLISTER PACK (49884-128-52)

49884- ENDO USA, Inc.
- 49884-158- Everolimus
  - 49884-158-02- 6 BLISTER PACK in 1 CARTON (49884-158-02) / 10 TABLET in 1 BLISTER PACK (49884-158-52)

49884- ENDO USA, Inc.
- 49884-159- Everolimus
  - 49884-159-02- 6 BLISTER PACK in 1 CARTON (49884-159-02) / 10 TABLET in 1 BLISTER PACK (49884-159-52)

49884- ENDO USA, Inc.
- 49884-160- Everolimus
  - 49884-160-02- 6 BLISTER PACK in 1 CARTON (49884-160-02) / 10 TABLET in 1 BLISTER PACK (49884-160-52)

49884- ENDO USA, Inc.
- 49884-283- Everolimus
  - 49884-283-02- 6 BLISTER PACK in 1 CARTON (49884-283-02) / 10 TABLET in 1 BLISTER PACK (49884-283-52)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-821- Everolimus
  - 51991-821-28- 4 BLISTER PACK in 1 CARTON (51991-821-28) / 7 TABLET in 1 BLISTER PACK (51991-821-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-821- Everolimus
  - 51991-821-33- 30 TABLET in 1 BOTTLE (51991-821-33)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-822- Everolimus
  - 51991-822-28- 4 BLISTER PACK in 1 CARTON (51991-822-28) / 7 TABLET in 1 BLISTER PACK (51991-822-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-822- Everolimus
  - 51991-822-33- 30 TABLET in 1 BOTTLE (51991-822-33)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-823- Everolimus
  - 51991-823-28- 4 BLISTER PACK in 1 CARTON (51991-823-28) / 7 TABLET in 1 BLISTER PACK (51991-823-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-823- Everolimus
  - 51991-823-33- 30 TABLET in 1 BOTTLE (51991-823-33)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-824- Everolimus
  - 51991-824-28- 4 BLISTER PACK in 1 CARTON (51991-824-28) / 7 TABLET in 1 BLISTER PACK (51991-824-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-824- Everolimus
  - 51991-824-33- 30 TABLET in 1 BOTTLE (51991-824-33)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-990- Everolimus
  - 51991-990-28- 4 BLISTER PACK in 1 CARTON (51991-990-28) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (51991-990-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-991- Everolimus
  - 51991-991-28- 4 BLISTER PACK in 1 CARTON (51991-991-28) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (51991-991-99)

51991- Breckenridge Pharmaceutical, Inc.
- 51991-992- Everolimus
  - 51991-992-28- 4 BLISTER PACK in 1 CARTON (51991-992-28) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (51991-992-99)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6234-
  - 52076-6234-1- 5 kg in 1 DOSE PACK (52076-6234-1)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6234-
  52076-6234-2- 50 kg in 1 DRUM (52076-6234-2)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6247-
  52076-6247-1- 1 kg in 1 DRUM (52076-6247-1)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6247-
  52076-6247-2- 5 kg in 1 DRUM (52076-6247-2)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6247-
  52076-6247-3- 50 kg in 1 DRUM (52076-6247-3)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6253-
  52076-6253-1- 1 kg in 1 DRUM (52076-6253-1)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6253-
  52076-6253-2- 5 kg in 1 DRUM (52076-6253-2)

52076- Chunghwa Chemical Synthesis & Biotech. Ltd
- 52076-6253-
  52076-6253-3- 50 kg in 1 DRUM (52076-6253-3)

54893- MSN Laboratories Private Limited
- 54893-0126-
  54893-0126-5- 15 kg in 1 DRUM (54893-0126-5)

60219- Amneal Pharmaceuticals NY LLC
- 60219-2279- EVEROLIMUS
  60219-2279-2- 4 BLISTER PACK in 1 CARTON (60219-2279-2) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2279-1)

60219- Amneal Pharmaceuticals NY LLC
- 60219-2280- EVEROLIMUS
  - 60219-2280-2- 4 BLISTER PACK in 1 CARTON (60219-2280-2) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2280-1)

60219- Amneal Pharmaceuticals NY LLC
- 60219-2281- EVEROLIMUS
  - 60219-2281-2- 4 BLISTER PACK in 1 CARTON (60219-2281-2) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2281-1)

62227- BrightGene Bio-Medical Technology Co., Ltd.
- 62227-019-
  - 62227-019-01- 1 kg in 1 BAG (62227-019-01)

63850- Natco Pharma Limited
- 63850-0058- Everolimus
  63850-0058-1- 4 BLISTER PACK in 1 CARTON (63850-0058-1) / 7 TABLET in 1 BLISTER PACK

63850- Natco Pharma Limited
- 63850-0058- Everolimus
  - 63850-0058-4- 30 TABLET in 1 BOTTLE (63850-0058-4)

63850- Natco Pharma Limited
- 63850-0059- Everolimus
  - 63850-0059-1- 4 BLISTER PACK in 1 CARTON (63850-0059-1) / 7 TABLET in 1 BLISTER PACK

63850- Natco Pharma Limited
- 63850-0059- Everolimus
  - 63850-0059-4- 30 TABLET in 1 BOTTLE (63850-0059-4)

63850- Natco Pharma Limited
- 63850-0060- Everolimus
  - 63850-0060-1- 4 BLISTER PACK in 1 CARTON (63850-0060-1) / 7 TABLET in 1 BLISTER PACK

63850- Natco Pharma Limited
- 63850-0060- Everolimus
  - 63850-0060-4- 30 TABLET in 1 BOTTLE (63850-0060-4)

63850- Natco Pharma Limited
- 63850-0061- Everolimus
  - 63850-0061-1- 4 BLISTER PACK in 1 CARTON (63850-0061-1) / 7 TABLET in 1 BLISTER PACK

63850- Natco Pharma Limited
- 63850-0061- Everolimus
  - 63850-0061-4- 30 TABLET in 1 BOTTLE (63850-0061-4)

63850- Natco Pharma Limited
- 63850-0062- Everolimus
  - 63850-0062-2- 6 BLISTER PACK in 1 CARTON (63850-0062-2) / 10 TABLET in 1 BLISTER PACK (63850-0062-3)

63850- Natco Pharma Limited
- 63850-0062- Everolimus
  - 63850-0062-6- 60 TABLET in 1 BOTTLE (63850-0062-6)

63850- Natco Pharma Limited
- 63850-0063- Everolimus
  - 63850-0063-2- 6 BLISTER PACK in 1 CARTON (63850-0063-2) / 10 TABLET in 1 BLISTER PACK (63850-0063-3)

63850- Natco Pharma Limited
- 63850-0063- Everolimus
  - 63850-0063-6- 60 TABLET in 1 BOTTLE (63850-0063-6)

63850- Natco Pharma Limited
- 63850-0064- Everolimus
  - 63850-0064-2- 6 BLISTER PACK in 1 CARTON (63850-0064-2) / 10 TABLET in 1 BLISTER PACK

63850- Natco Pharma Limited
- 63850-0064- Everolimus
  - 63850-0064-6- 60 TABLET in 1 BOTTLE (63850-0064-6)

65129- ScinoPharm Taiwan Ltd.
- 65129-1324-
  - 65129-1324-0- 10 kg in 1 BAG (65129-1324-0)

65727- Biocon Limited
- 65727-046-
  65727-046-01- 1 kg in 1 DRUM (65727-046-01)

65727- Biocon Limited
- 65727-063-
  65727-063-01- 1 kg in 1 DRUM (65727-063-01)

65727- Biocon limited
- 65727-064-
  65727-064-01- 1 kg in 1 DRUM (65727-064-01)

67877- Ascend Laboratories, LLC
- 67877-718- Everolimus
  67877-718-31- 6 BLISTER PACK in 1 CARTON (67877-718-31) / 10 TABLET in 1 BLISTER PACK (67877-718-33)

67877- Ascend Laboratories, LLC
- 67877-718- Everolimus
  - 67877-718-60- 60 TABLET in 1 BOTTLE (67877-718-60)

67877- Ascend Laboratories, LLC
- 67877-719- Everolimus
  - 67877-719-31- 6 BLISTER PACK in 1 CARTON (67877-719-31) / 10 TABLET in 1 BLISTER PACK (67877-719-33)

67877- Ascend Laboratories, LLC
- 67877-719- Everolimus
  - 67877-719-60- 60 TABLET in 1 BOTTLE (67877-719-60)

67877- Ascend Laboratories, LLC
- 67877-720- Everolimus
  - 67877-720-31- 6 BLISTER PACK in 1 CARTON (67877-720-31) / 10 TABLET in 1 BLISTER PACK (67877-720-33)

67877- Ascend Laboratories, LLC
- 67877-720- Everolimus
  - 67877-720-60- 60 TABLET in 1 BOTTLE (67877-720-60)

67877- Ascend Laboratories, LLC
- 67877-721- Everolimus
  - 67877-721-31- 6 BLISTER PACK in 1 CARTON (67877-721-31) / 10 TABLET in 1 BLISTER PACK (67877-721-33)

67877- Ascend Laboratories, LLC
- 67877-721- Everolimus
  - 67877-721-60- 60 TABLET in 1 BOTTLE (67877-721-60)

68254- CONCORD BIOTECH LTD
- 68254-6234-
  - 68254-6234-2- 1 BAG in 1 BOTTLE (68254-6234-2) / 1 kg in 1 BAG

70225- NATCO PHARMA LIMITED
- 70225-1103-
  70225-1103-3- 1 kg in 1 DRUM (70225-1103-3)

70377- Biocon Pharma Inc.
- 70377-010- EVEROLIMUS
  70377-010-11- 30 TABLET in 1 BOTTLE (70377-010-11)

70377- Biocon Pharma Inc.
- 70377-010- EVEROLIMUS
  - 70377-010-22- 4 BLISTER PACK in 1 CARTON (70377-010-22) / 7 TABLET in 1 BLISTER PACK

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆